Temperature-sensitive liposomes for co-delivery of tamoxifen and imatinib for synergistic breast cancer treatment

References

• Bredlau, A.L., et al., 2018. Localized delivery of therapeutic doxorubicin dose across the canine blood-brain barrier with hyperthermia and temperature sensitive liposomes. Drug Delivery, 25 (1), 973–984.
   PubMed Web of Science ®Google Scholar
• Bonneterre, J., et al., 2001. Anastrozole is superior to tamoxifen as first‐line therapy in hormone receptor positive advanced breast carcinoma. Cancer, 92 (9), 2247–2258.
   PubMed Web of Science ®Google Scholar
• Chaudhary, P.M., and Roninson, I.B., 1993. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. Journal of the national cancer institute, 85 (8), 632–639.
   PubMedGoogle Scholar
• Chou, T.C., 2010. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer research, 70 (2), 440–446.
   PubMed Web of Science ®Google Scholar
• Cleator, S., Heller, W., and Coombes, R.C., 2007. Triple-negative breast cancer: therapeutic options. Lancet oncology, 8 (3), 235–244.
   PubMed Web of Science ®Google Scholar
• Cohen, M.H., et al., 2002. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clinical cancer research, 8 (5), 935–942.
   PubMed Web of Science ®Google Scholar
• Cristofanilli, M., et al., 2008. Imatinib mesylate (Gleevec®) in advanced breast cancer-expressing C-Kit or PDGFR-β: clinical activity and biological correlations. Annals of oncology, 19 (10), 1713–1719.
   PubMed Web of Science ®Google Scholar
• Danhier, F., Feron, O., and Préat, V., 2010. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. Journal of controlled release, 148 (2), 135–146.
   PubMed Web of Science ®Google Scholar
• Demetri, G.D., et al., 2002. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. New England journal of medicine, 347 (7), 472–480.
   PubMed Web of Science ®Google Scholar
• Fan, L., et al., 2010. Co-delivery of PDTC and doxorubicin by multifunctional micellar nanoparticles to achieve active targeted drug delivery and overcome multidrug resistance. Biomaterials, 31 (21), 5634–5642.
   PubMed Web of Science ®Google Scholar
• Greene, G.L., et al., 1984. Immunochemical studies of estrogen receptors. Journal of steroid biochemistry, 20 (1), 51–56.
   PubMedGoogle Scholar
• Guo, J., et al., 2011. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. Journal of clinical oncology, 29 (21), 2904–2909.
   PubMed Web of Science ®Google Scholar
• Heinrich, M.C., et al., 2008. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. Journal of clinical oncology, 26 (33), 5360–5367.
   PubMed Web of Science ®Google Scholar
• Hu, F., Neoh, K., and Kang, E., 2006. Synthesis and in vitro anti-cancer evaluation of tamoxifen-loaded magnetite/PLLA composite nanoparticles. Biomaterials, 27 (33), 5725–5733.
   PubMed Web of Science ®Google Scholar
• Immordino, M.L., Dosio, F., and Cattel, L., 2006. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. International journal of nanomedicine, 1, 297–312.
   PubMed Web of Science ®Google Scholar
• Jiang, Q., Zheng, S., and Wang, G., 2013. Development of new estrogen receptor-targeting therapeutic agents for tamoxifen-resistant breast cancer. Future medicinal chemistry, 5 (9), 1023–1035.
   PubMed Web of Science ®Google Scholar
• Joy, A., et al., 2015. Systemic treatment approaches in her2-negative advanced breast cancer-guidance on the guidelines. Current oncology, 22 (Suppl 1), S29.
   PubMedGoogle Scholar
• Kalepu, S., and Nekkanti, V., 2015. Insoluble drug delivery strategies: review of recent advances and business prospects. Acta Pharmaceutica Sinica B, 5 (5), 442–453.
   PubMed Web of Science ®Google Scholar
• Korkola, J.E., et al., 2003. Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis. Cancer research, 63 (21), 7167–7175.
   PubMed Web of Science ®Google Scholar
• Krag, D., et al., 1993. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surgical oncology, 2 (6), 335–340.
   PubMed Web of Science ®Google Scholar
• Kulkarni, S., Betageri, G., and Singh, M., 1995. Factors affecting microencapsulation of drugs in liposomes. Journal of microencapsulation, 12 (3), 229–246.
   PubMed Web of Science ®Google Scholar
• La Thangue, N.B., and Kerr, D.J., 2011. Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nature reviews clinical oncology, 8 (10), 587–596.
   PubMed Web of Science ®Google Scholar
• Li, C.I., et al., 2003. Trends in incidence rates of invasive lobular and ductal breast carcinoma. Journal of the American medical association, 289 (11), 1421–1424.
   PubMed Web of Science ®Google Scholar
• Li, H.F., et al., 2015. Targeted and controlled drug delivery using a temperature and ultra-violet responsive liposome with excellent breast cancer suppressing ability. RSC advances, 5 (35), 27630–27639.
   Web of Science ®Google Scholar
• Lin, Y.L., et al., 2016. Inhibition of breast cancer with transdermal tamoxifen-encapsulated lipoplex. Journal of nanobiotechnology, 14, 11.
   PubMed Web of Science ®Google Scholar
• Manna, S., and Holz, M.K., 2016. Tamoxifen action in ER-negative breast cancer. Signal transduction insights, 5, 1–7.
   PubMedGoogle Scholar
• McIntosh, T., et al., 1995. Experimental tests for protrusion and undulation pressures in phospholipid bilayers. Biochemistry, 34 (27), 8520–8532.
   PubMed Web of Science ®Google Scholar
• McPherson, K.C., and Steel, D.J.M., 2000. ABC of breast diseases: breast cancer-epidemiology, risk factors, and genetics. British medical journal, 321 (7261), 624.
   PubMed Web of Science ®Google Scholar
• Mills, J.K., and Needham, D., 2005. Lysolipid incorporation in dipalmitoylphosphatidylcholine bilayer membranes enhances the ion permeability and drug release rates at the membrane phase transition. Biochim biophys acta, 1716 (2), 77–96.
   PubMed Web of Science ®Google Scholar
• Monteagudo, E., et al., 2012. Development, characterization, and in vitro evaluation of tamoxifen microemulsions. Journal of drug delivery, 2012, 1–11.
   Google Scholar
• Nagarajan, S., et al., 2012. Dynamics of the gel to fluid phase transformation in unilamellar DPPC vesicles. Journal of physical chemistry B, 116 (46), 13749–13756.
   PubMed Web of Science ®Google Scholar
• Needham, D., et al., 2000. A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer research, 60, 1197–1201.
   PubMed Web of Science ®Google Scholar
• O'Regan, R.M., and Jordan, V.C., 2002. The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators. Lancet oncology, 3 (4), 207–214.
   PubMed Web of Science ®Google Scholar
• Ponce, A.M., et al., 2007. Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects. Journal of the national cancer institute, 99 (1), 53–63.
   PubMed Web of Science ®Google Scholar
• Shiau, A.K., et al., 1998. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell, 95 (7), 927–937.
   PubMed Web of Science ®Google Scholar
• Schwendener, R.A., and Schott, H., 2010. Liposome formulations of hydrophobic drugs. liposomes: methods and protocols. In: V. Weissig, ed. Volume 1: Pharmaceutical Nanocarriers, 129. New York City, NY: Humana Press.
   Google Scholar
• Siegel, R.L., Miller, K.D., and Jemal, A., 2016. Cancer statistics, 2016. CA: cancer journal for clinicians , 66 (1), 7–30.
   PubMed Web of Science ®Google Scholar
• Slamon, D.J., et al., 2001. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New England journal of medicine, 344 (11), 783–792.
   PubMed Web of Science ®Google Scholar
• Szmigielski, S., et al., 1988. Local microwave hyperthermia in treatment of advanced prostatic adenocarcinoma. Urological research, 16 (1), 1–7.
   PubMedGoogle Scholar
• van der Zee, J., 2002. Heating the patient: a promising approach? Annals of oncology, 13 (8), 1173–1184.
   PubMed Web of Science ®Google Scholar
• van Leeuwen, R.W., et al., 2014. Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective. Lancet oncology, 15 (8), e315–e326.
   PubMed Web of Science ®Google Scholar
• Wang, H., et al., 2011. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Biomaterials, 32 (32), 8281–8290.
   PubMed Web of Science ®Google Scholar